strategic-partnerships-en
Strategic Collaboration Agreement Signed Between Nojine Zist Pharmed and Pasteur Institute of Iran
Read Time: 3 mins
September 18, 2026
CLINICAL DEVELOPMENT
Development of New Plasma-Derived Pharmaceutical Product Portfolio This Year
Date: July 29, 2026
|
Read Time: 8 mins
nojin Zist Pharmed's pharmaceutical portfolio is developing new clinical treatment options in line with maximizing the coverage of the country's therapeutic needs.
Clinical Phases and References for New Drug Monograph Registration
The initial focus of our production lines has been on the sustainable supply of 20% Albumin (Albugin) and 5% Intravenous Immunoglobulin (Immunogin). With the completion of clinical stability studies and the registration of technical dossiers (CTD), this year we will witness the entry of Factor VIII coagulation products and specific immunoglobulins (such as Anti-Hepatitis B and Anti-Tetanus) into the country’s hospital distribution chain.
Continuous enhancement of the variety of the biological product portfolio minimizes the need to import licensed products.
Vision for National Hemodynamic Self-Sufficiency
nojin’s clinical development program, utilizing localized clinical trial data and continuous Pharmacovigilance, guarantees 100% safety of the new pharmaceutical portfolio in post-marketing phases (Phase IV).
Related Research Findings
rnd-production-en
Nojine Achieves 100% Pharmacopoeial Compliance Under WHO-GMP Biological Standards
Read Time: 5 mins
September 18, 2026
events-conferences-en
Nojine Scientists Present Breakthrough Clinical Research at 25th International Congress of Pharmaceutical Biotechnology
Read Time: 4 mins
September 18, 2026